HepaRegeniX
Germany - TübingenBiotechnology
Focus: HepaRegeniX is a private German biotech focused on small molecule MKK4 inhibitors targeting acute and chronic liver diseases, particularly in gastroenterology. The company is at an early stage with a single Phase 1/2 program.
Profile data last refreshed Yesterday · AI intelligence enriched 2w ago
Funding Stage
PRIVATE
Open Jobs
0
About HepaRegeniX
AI assessmentNot HiringNo open roles listed right now. Follow HepaRegeniX to get notified when they start hiring — the background below is worth knowing for when they do.
Why Work Here
Data completeness
1/9 — Limited
Company HealthSolid
Pipeline
Early-stage
1 total
LOE Risk
Protected
No near-term cliffs
Hiring
0 open
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
Pipeline & Clinical Trials
HRX215 capsules
Colorectal Liver MetastasesClinical Trials (1)
NCT06638502Safety of HRX215 in Patients After Minor and Major Liver Resection
Phase 1/2Help build intelligence for HepaRegeniX
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.